FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 301:126-131 July 19, 1979 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We compared amphotericin B therapy for cryptococcal meningitis with a newer regimen containing both amphotericin B and flucytosine. In 50 patients with 51 courses of therapy adherent to the protocol, 27 courses were with amphotericin B and 24 with the combination. Even though the combination regimen was given for only six weeks and amphotericin B for 10 weeks, the combination cured or improved more patients (16 vs 11), produced fewer failures or relapses (three vs. 11), more rapid sterilization of the cerebrospinal fluid (P less than 0.001) and less nephrotoxicity (P less than 0.05) than did amphotericin B alone. The number of deaths was the same (five) with each regimen. Adverse reactions to flucytosine occurred in 11 of 34 patients but were not life threatening. We conclude that combined flucytosine-amphoericin B therapy is the regimen of choice in cryptococcal meningitis.

This article has been cited by other articles:

• Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]  
• Johnson, E. M. (2008). Issues in antifungal susceptibility testing. J Antimicrob Chemother 61: i13-i18 [Abstract] [Full Text]  
• Schwarz, P., Janbon, G., Dromer, F., Lortholary, O., Dannaoui, E. (2007). Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51: 383-385 [Abstract] [Full Text]  
• Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., Denning, D. W. (2006). Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. Antimicrob. Agents Chemother. 50: 3680-3688 [Abstract] [Full Text]  
• Enoch, D. A., Ludlam, H. A., Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol 55: 809-818 [Abstract] [Full Text]  
• Duffalo, M. L. (2006). Fungal Opportunistic Infections in HIV Disease. Journal of Pharmacy Practice 19: 17-30 [Abstract]  
• Schwarz, P., Dromer, F., Lortholary, O., Dannaoui, E. (2006). Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis. Antimicrob. Agents Chemother. 50: 113-120 [Abstract] [Full Text]  
• Serena, C., Fernandez-Torres, B., Pastor, F. J., Trilles, L., Lazera, M. d. S., Nolard, N., Guarro, J. (2005). In Vitro Interactions of Micafungin with Other Antifungal Drugs against Clinical Isolates of Four Species of Cryptococcus. Antimicrob. Agents Chemother. 49: 2994-2996 [Abstract] [Full Text]  
• Mylonakis, E., Moreno, R., El Khoury, J. B., Idnurm, A., Heitman, J., Calderwood, S. B., Ausubel, F. M., Diener, A. (2005). Galleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis. Infect. Immun. 73: 3842-3850 [Abstract] [Full Text]  
• Larsen, R. A., Pappas, P. G., Perfect, J., Aberg, J. A., Casadevall, A., Cloud, G. A., James, R., Filler, S., Dismukes, W. E. (2005). Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis. Antimicrob. Agents Chemother. 49: 952-958 [Abstract] [Full Text]  
• Gaziano, R., Bozza, S., Bellocchio, S., Perruccio, K., Montagnoli, C., Pitzurra, L., Salvatori, G., De Santis, R., Carminati, P., Mantovani, A., Romani, L. (2004). Anti-Aspergillus fumigatus Efficacy of Pentraxin 3 Alone and in Combination with Antifungals. Antimicrob. Agents Chemother. 48: 4414-4421 [Abstract] [Full Text]  
• Cuenca-Estrella, M. (2004). Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54: 854-869 [Abstract] [Full Text]  
• Barchiesi, F., Spreghini, E., Schimizzi, A. M., Maracci, M., Giannini, D., Carle, F., Scalise, G. (2004). Posaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection. Antimicrob. Agents Chemother. 48: 3312-3316 [Abstract] [Full Text]  
• Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
• Larsen, R. A., Bauer, M., Thomas, A. M., Graybill, J. R. (2004). Amphotericin B and Fluconazole, a Potent Combination Therapy for Cryptococcal Meningitis. Antimicrob. Agents Chemother. 48: 985-991 [Abstract] [Full Text]  
• Miller, J. L., Schell, W. A., Wills, E. A., Toffaletti, D. L., Boyce, M., Benjamin, D. K. Jr., Bartroli, J., Perfect, J. R. (2004). In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 48: 384-387 [Abstract] [Full Text]  
• Schwarz, P., Dromer, F., Lortholary, O., Dannaoui, E. (2003). In Vitro Interaction of Flucytosine with Conventional and New Antifungals against Cryptococcus neoformans Clinical Isolates. Antimicrob. Agents Chemother. 47: 3361-3364 [Abstract] [Full Text]  
• Pacetti, S. A, Gelone, S. P (2003). Caspofungin Acetate for Treatment of Invasive Fungal Infections. The Annals of Pharmacotherapy 37: 90-98 [Abstract] [Full Text]  
• Jean, S.-S., Fang, C.-T., Shau, W.-Y., Chen, Y.-C., Chang, S.-C., Hsueh, P.-R., Hung, C.-C., Luh, K.-T. (2002). Cryptococcaemia: clinical features and prognostic factors. QJM 95: 511-518 [Abstract] [Full Text]  
• Barchiesi, F., Schimizzi, A. M., Najvar, L. K., Bocanegra, R., Caselli, F., Di Cesare, S., Giannini, D., Di Francesco, L. F., Giacometti, A., Carle, F., Scalise, G., Graybill, J. R. (2001). Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 1355-1359 [Abstract] [Full Text]  
• Manavathu, E. K., Dimmock, J. R., Vashishtha, S. C., Chandrasekar, P. H. (2001). Inhibition of H+-ATPase-mediated proton pumping in Cryptococcus neoformans by a novel conjugated styryl ketone. J Antimicrob Chemother 47: 491-494 [Abstract] [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Furukawa, K., Sasaki, H., Pollard, R. B., Suzuki, F. (2000). Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother 46: 443-450 [Abstract] [Full Text]  
• Barchiesi, F., Schimizzi, A. M., Caselli, F., Novelli, A., Fallani, S., Giannini, D., Arzeni, D., Di Cesare, S., Di Francesco, L. F., Fortuna, M., Giacometti, A., Carle, F., Mazzei, T., Scalise, G. (2000). Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2435-2441 [Abstract] [Full Text]  
• Vermes, A., Guchelaar, H.-J., Dankert, J. (2000). Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46: 171-179 [Abstract] [Full Text]  
• Andes, D., van Ogtrop, M. (2000). In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model. Antimicrob. Agents Chemother. 44: 938-942 [Abstract] [Full Text]  
• Shih, C.-C., Chen, Y.-C., Chang, S.-C., Luh, K.-T., Hsieh, W.-C. (2000). Cryptococcal meningitis in non-HIV-infected patients. QJM 93: 245-251 [Abstract] [Full Text]  
• Rodero, L., Cordoba, S., Cahn, P., Hochenfellner, F., Davel, G., Canteros, C., Kaufman, S., Guelfand, L. (2000). In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J Antimicrob Chemother 45: 239-242 [Abstract] [Full Text]  
• Barchiesi, F., Gallo, D., Caselli, F., Di Francesco, L. F., Arzeni, D., Giacometti, A., Scalise, G. (1999). In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 44: 65-70 [Abstract] [Full Text]  
• Sarosi, G. A. (1999). Cryptococcal Lung Disease in Patients Without HIV Infection. Chest 115: 610-611 [Full Text]  
• Schell, W. A., De Almeida, G. M. D., Dodge, R. K., Okonogi, K., Perfect, J. R. (1998). In Vitro and In Vivo Efficacy of the Triazole TAK-187 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42: 2630-2632 [Abstract] [Full Text]  
• Lewis, R. E., Lund, B. C., Klepser, M. E., Ernst, E. J., Pfaller, M. A. (1998). Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination against Candida albicans by Using a Dynamic In Vitro Mycotic Infection Model. Antimicrob. Agents Chemother. 42: 1382-1386 [Abstract] [Full Text]  
• Diamond, D. M., Bauer, M., Daniel, B. E., Leal, M. A. E., Johnson, D., Williams, B. K., Thomas, A. M., Ding, J. C., Najvar, L., Graybill, J. R., Larsen, R. A. (1998). Amphotericin B Colloidal Dispersion Combined with Flucytosine with or without Fluconazole for Treatment of Murine Cryptococcal Meningitis. Antimicrob. Agents Chemother. 42: 528-533 [Abstract] [Full Text]  
• van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., Powderly, W. G., Dismukes, W. E., The National Institute of Allergy and Infectious D, (1997). Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. NEJM 337: 15-21 [Abstract] [Full Text]  
• Como, J. A., Dismukes, W. E. (1994). Oral Azole Drugs as Systemic Antifungal Therapy. NEJM 330: 263-272 [Full Text]  
• Paar, D., Masur, H. (1992). Advances in the Management of Major Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. Journal of Pharmacy Practice 5: 131-142  
• Mayer, K. H. (1986). The Clinical Challenges of AIDS and HIV Infection. J Law Med Ethics 14: 281-289